134 related articles for article (PubMed ID: 24836152)
1. Re: Rana R. McKay, Xun Lin, Julia J. Perkins, Daniel Y.C. Heng, Ronit Simantov, Toni K. Choueiri. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. Eur Urol 2014;66:502-9.
Beuselinck B; Wolter P; Broom R
Eur Urol; 2014 Sep; 66(3):e53-4. PubMed ID: 24836152
[No Abstract] [Full Text] [Related]
2. Re: Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
Tu SM; Chen AH
Can J Urol; 2012 Jun; 19(3):6268. PubMed ID: 22704311
[No Abstract] [Full Text] [Related]
3. Assessment of the impact of targeted therapy on metastatic bone disease in renal cancer.
Brown JE; Wood SL
Eur Urol; 2014 Sep; 66(3):510-1. PubMed ID: 24746971
[No Abstract] [Full Text] [Related]
4. Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy.
Mignogna MD; Fedele S; Lo Russo L; Ciccarelli R; Lo Muzio L
J Clin Oncol; 2006 Mar; 24(9):1475-7. PubMed ID: 16549843
[No Abstract] [Full Text] [Related]
5. Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report.
Kijima T; Fujii Y; Suyama T; Okubo Y; Yonese J; Fukui I
Int J Urol; 2008 Jun; 15(6):546-7. PubMed ID: 18489646
[TBL] [Abstract][Full Text] [Related]
6. Recurrent scrotal hemangiomas during treatment with sunitinib.
Tonini G; Intagliata S; Cagli B; Segreto F; Perrone G; Onetti Muda A; Santini D; Persichetti P
J Clin Oncol; 2010 Dec; 28(35):e737-8. PubMed ID: 20823408
[No Abstract] [Full Text] [Related]
7. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate.
Kijima T; Fujii Y; Suyama T; Okubo Y; Yamamoto S; Masuda H; Yonese J; Fukui I
BJU Int; 2009 Mar; 103(5):620-4. PubMed ID: 18990143
[TBL] [Abstract][Full Text] [Related]
8. Reply from authors re: Bertrand Tombal. Zometa European Study (ZEUS): another failed crusade for the holy grail of prostate cancer bone metastases prevention? Eur Urol 2015;67:492-4: ZEUS: the quest for the holy grail of prostate cancer bone metastases prevention continues.
Witjes WP; Patel A; Wirth M
Eur Urol; 2015 Mar; 67(3):494-5. PubMed ID: 24726855
[No Abstract] [Full Text] [Related]
9. Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases.
Tunn UW; Stenzl A; Schultze-Seemann W; Strauss A; Kindler M; Miller K; Wirth MP; Zantl N; Schulze M; May C; Ruebel A; Birkholz K; Gruenwald V
Can J Urol; 2012 Jun; 19(3):6261-7. PubMed ID: 22704310
[TBL] [Abstract][Full Text] [Related]
10. A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy.
Miwa S; Mizokami A; Konaka H; Izumi K; Nohara T; Namiki M
Jpn J Clin Oncol; 2009 Nov; 39(11):745-50. PubMed ID: 19808839
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer.
Saad F; Eastham JA
Semin Oncol; 2010 Jun; 37 Suppl 1():S38-44. PubMed ID: 20682371
[TBL] [Abstract][Full Text] [Related]
12. Concurrent application of bisphosphonates and external beam radiotherapy in patients with metastatic bone disease from renal cancer.
Vassiliou V; Leotsinides M; Kalogeropoulou C; Kardamakis D
BJU Int; 2009 Aug; 104(3):417-8; author reply 418. PubMed ID: 19614659
[No Abstract] [Full Text] [Related]
13. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Smidt-Hansen T; Folkmar TB; Fode K; Agerbaek M; Donskov F
J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
[TBL] [Abstract][Full Text] [Related]
14. Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma.
Phillips PM; Newman SA
Arch Ophthalmol; 2008 Jan; 126(1):137-9. PubMed ID: 18195236
[No Abstract] [Full Text] [Related]
15. Zoledronic acid enhances the effect of radiotherapy for bone metastases from renal cell carcinomas: more than a 24-month median follow-up.
Takeda N; Isu K; Hiraga H; Shinohara N; Minami A; Kamata H
J Orthop Sci; 2012 Nov; 17(6):770-4. PubMed ID: 23053582
[TBL] [Abstract][Full Text] [Related]
16. Long-term bisphosphonate treatment of bone metastases from renal cell carcinoma.
Michaelson MD; Rosenthal DI; Smith MR
J Clin Oncol; 2004 Oct; 22(20):4233-4. PubMed ID: 15483039
[No Abstract] [Full Text] [Related]
17. Re: Toni K. Choueiri, Daniel Y.C. Heng, Jae Lyun Lee, et al. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. JAMA Oncol. In press. https://doi.org/10.1001/jamaoncol.2020.2218: SAVOIR: From Own Goal to Winning Goal?
Mollica V; Rizzo A; Massari F
Eur Urol Oncol; 2020 Aug; 3(4):561-562. PubMed ID: 32653414
[No Abstract] [Full Text] [Related]
18. The use of zoledronic acid in pediatric cancer patients.
August KJ; Dalton A; Katzenstein HM; George B; Olson TA; Wasilewski-Masker K; Rapkin LB
Pediatr Blood Cancer; 2011 Apr; 56(4):610-4. PubMed ID: 21298747
[TBL] [Abstract][Full Text] [Related]
19. Words of Wisdom. Re: Randomized Controlled Trial of Early Zoledronic Acid in Men with Castration-sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance).
Kimura T; Egawa S
Eur Urol; 2016 Apr; 69(4):754-5. PubMed ID: 26972498
[No Abstract] [Full Text] [Related]
20. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
Saad F; Lipton A
BJU Int; 2006 Jun; 97(6):1351-2. PubMed ID: 16686742
[No Abstract] [Full Text] [Related]
[Next] [New Search]
